Clinical outcomes of otogenic skull base osteomyelitis
- PDF / 747,259 Bytes
- 6 Pages / 595.276 x 790.866 pts Page_size
- 56 Downloads / 218 Views
OTOLOGY
Clinical outcomes of otogenic skull base osteomyelitis Da Jung Jung1 · Jisong Hong1 · Hyung Joon Cho1 · Myung Hoon Yoo1 · Kyu‑Yup Lee1 Received: 28 May 2020 / Accepted: 10 September 2020 © Springer-Verlag GmbH Germany, part of Springer Nature 2020
Abstract Purpose Skull base osteomyelitis (SBO) is an uncommon and a potentially life-threatening condition if not promptly recognized and properly treated. The aim of our study was to present a 32-case series of patients diagnosed with SBO at a single center. Methods In this retrospective study, we reviewed the data of patients diagnosed with otogenic SBO between January 2011 and January 2020. 32 patients were enrolled in the study. SBO diagnosis was based on a combination of symptoms and physical examination, bone scan, brain magnetic resonance imaging, and pathologic examination findings. The following clinical data were collected during the follow-up period: types of antibiotics used, duration of antibiotic treatment, C-reactive protein level, presence of disease control, duration from the onset of symptoms to diagnosis, and patient survival. Results The mean follow-up period was 11 (1–110) months. The mean duration of antibiotic treatment was 115 (19– 223) days. The mean C-reactive protein levels at the time of diagnosis and at the endpoint of follow-up were 3.05 (0.56–18.31) and 0.21 (0.03–33.61) mg/dL, respectively (P
Data Loading...
